JP2013531008A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531008A5
JP2013531008A5 JP2013518242A JP2013518242A JP2013531008A5 JP 2013531008 A5 JP2013531008 A5 JP 2013531008A5 JP 2013518242 A JP2013518242 A JP 2013518242A JP 2013518242 A JP2013518242 A JP 2013518242A JP 2013531008 A5 JP2013531008 A5 JP 2013531008A5
Authority
JP
Japan
Prior art keywords
carbon atoms
enantiomer
pharmaceutical composition
composition according
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518242A
Other languages
English (en)
Japanese (ja)
Other versions
JP5921539B2 (ja
JP2013531008A (ja
Filing date
Publication date
Priority claimed from US12/827,529 external-priority patent/US8623913B2/en
Application filed filed Critical
Publication of JP2013531008A publication Critical patent/JP2013531008A/ja
Publication of JP2013531008A5 publication Critical patent/JP2013531008A5/ja
Application granted granted Critical
Publication of JP5921539B2 publication Critical patent/JP5921539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518242A 2010-06-30 2011-06-27 下肢静止不能症候群を治療する方法 Active JP5921539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,529 2010-06-30
US12/827,529 US8623913B2 (en) 2010-06-30 2010-06-30 Methods for treating restless legs syndrome
PCT/KR2011/004677 WO2012002688A2 (en) 2010-06-30 2011-06-27 Methods of treating restless legs syndrome

Publications (3)

Publication Number Publication Date
JP2013531008A JP2013531008A (ja) 2013-08-01
JP2013531008A5 true JP2013531008A5 (US07794700-20100914-C00152.png) 2014-08-07
JP5921539B2 JP5921539B2 (ja) 2016-05-24

Family

ID=45400169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518242A Active JP5921539B2 (ja) 2010-06-30 2011-06-27 下肢静止不能症候群を治療する方法

Country Status (9)

Country Link
US (1) US8623913B2 (US07794700-20100914-C00152.png)
EP (1) EP2588099B1 (US07794700-20100914-C00152.png)
JP (1) JP5921539B2 (US07794700-20100914-C00152.png)
KR (1) KR101785072B1 (US07794700-20100914-C00152.png)
CN (1) CN103025326B (US07794700-20100914-C00152.png)
CA (1) CA2801243C (US07794700-20100914-C00152.png)
ES (1) ES2638074T3 (US07794700-20100914-C00152.png)
HK (1) HK1178796A1 (US07794700-20100914-C00152.png)
WO (1) WO2012002688A2 (US07794700-20100914-C00152.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
EP2445490B1 (en) 2009-06-22 2023-02-08 SK Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
CN102781436B (zh) * 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
RU2689984C2 (ru) 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
ES2812586T3 (es) 2013-07-18 2021-03-17 Jazz Pharmaceuticals Ireland Ltd Tratamiento para la obesidad
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3509582B1 (en) 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
WO2018067971A1 (en) * 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses therof
CN111201014A (zh) 2017-06-02 2020-05-26 爱尔兰贾兹制药有限公司 治疗过度嗜睡的方法和组合物
EP3661911A4 (en) 2017-07-31 2021-04-14 Jazz Pharmaceuticals Ireland Limited CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF
US11283085B1 (en) 2020-03-06 2022-03-22 Bloom Energy Corporation Low VOC ink compositions and methods of forming fuel cell system components using the same
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11515543B1 (en) 2020-06-03 2022-11-29 Bloom Energy Corporation Aqueous fuel cell system component ink compositions and methods of forming fuel cell system components using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
KR20010043032A (ko) 1998-04-28 2001-05-25 도모따께 다께시 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
NZ527994A (en) 2001-02-27 2005-11-25 Ortho Mcneil Pharm Inc Carbamate compounds for use in the treatment of pain
PL364679A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療又は予防用nr2b受容体拮抗薬
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
WO2004026868A1 (en) 2002-09-20 2004-04-01 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
BRPI0414105B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de benzimidazolona com atividade agonista do receptor 5-ht4
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US8729120B2 (en) 2004-10-28 2014-05-20 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
MX2007012463A (es) 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US8440715B2 (en) * 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EA200970377A1 (ru) * 2006-10-13 2009-10-30 Янссен Фармацевтика Нв Композиции фенилалкиламинокарбамата
US7377267B2 (en) * 2006-10-30 2008-05-27 Ford Global Technologies, Llc Injection strategy to maximize efficiency in gaseous engine
CN101317949A (zh) * 2008-07-15 2008-12-10 洛阳梓生科技开发有限公司 一种补血调经养血柔肝胶囊的制作方法
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2445490B1 (en) 2009-06-22 2023-02-08 SK Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue

Similar Documents

Publication Publication Date Title
JP2013531008A5 (US07794700-20100914-C00152.png)
JP2013533253A5 (US07794700-20100914-C00152.png)
MY177250A (en) Novel nicotinamide derivative or salt thereof
JP2015505296A5 (US07794700-20100914-C00152.png)
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
JP2013509392A5 (US07794700-20100914-C00152.png)
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
JP2011037901A5 (US07794700-20100914-C00152.png)
EA201391341A1 (ru) Производные гетероциклических аминов
JP2013536188A5 (US07794700-20100914-C00152.png)
JP2016503797A5 (US07794700-20100914-C00152.png)
MY168937A (en) Ethynyl derivatives as modulators of mglur5 receptor activity
JP2014505107A5 (US07794700-20100914-C00152.png)
JP2013507369A5 (US07794700-20100914-C00152.png)
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF
JP2012521353A5 (US07794700-20100914-C00152.png)
CA2722102A1 (en) Phenylpropionic acid derivative and use thereof
PH12015502692B1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
UA102397C2 (ru) Производные индола как активаторы nurr-1 и их применение для лечения болезни паркинсона
JP2011006409A5 (US07794700-20100914-C00152.png)
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
UA114008C2 (xx) Похідні етинілу як модулятори активності рецептора mglur5
NZ714111A (en) Alpha-substituted glycinamide derivative
JP2010523540A5 (US07794700-20100914-C00152.png)